Triple antibody therapy shows promise for long-lasting HIV control

“Overall, our study showed that three anti-HIV antibodies with significant breadth of neutralization were actually able to maintain virological suppression in the absence of ART at least during the dosing period in a majority of the participants,” said co-corresponding author Boris Juelg, MD, Ph.D., a principal investigator at the Ragon Institute of MGH, MIT, and Harvard.

“In a smaller subset, this control was maintained up to week 44 even when the antibodies had reached very low levels in the blood. Future studies are now needed to determine the exact mechanisms of control and how long it can last.”

“Our data shows that broadly neutralizing antibodies may offer a new treatment strategy for HIV,” said Barouch, who is also the William Bosworth Castle Professor of Medicine at Harvard Medical School. Read Full Article…